the first topical treatment specifically approved for chronic hand eczema (CHE). The launch of pan-JAK inhibitor Anzupgo (delgocitinib) comes after the European Commission approved the drug last ...

a treatment for chronic hand eczema (CHE) considered to be its top pipeline prospect. The EMA's human medicines committee, the CHMP, delivered a positive opinion on the drug at its meeting ahead ...

In others, they are considered only if eczema symptoms worsen or fail to respond to conservative treatment. These drugs are sometimes used on their own or in combination with other treatments. Topical ...

Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...

H.C. Wainwright launched its coverage of eczema drug developer Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy recommendation ...

Previous studies suggest that patients older than 60 who develop chronic, unexplained eczema are taking more drugs than patients of the same age without eczema and that elderly patients with ...

Gilead continues its divergence out of its original infectious disease beginnings and into cancer and now, more deeply than ...

Lutikizumab is under clinical development by AbbVie and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase II drugs for Atopic Dermatitis (Atopic Eczema) have ...

Learn about rheumatoid vasculitis, neutrophilic dermatoses, and other rheumatoid arthritis rashes, their symptoms, and when ...

A monoclonal antibody that targets interleukin (IL)-31 receptor alpha, nemolizumab is specifically indicated for individuals 12 years and older with eczema ... with the drug, and the warnings ...

MY-004 is under clinical development by Createrna Science and Technology and currently in Phase II for Atopic Dermatitis (Atopic Eczema).